Estimation of Cachexia among Cancer Patients Based on Four Definitions by Fox, Kathleen M. et al.
Hindawi Publishing Corporation
Journal of Oncology
Volume 2009, Article ID 693458, 7 pages
doi:10.1155/2009/693458
Clinical Study
Estimation of Cachexia among Cancer Patients
Basedon FourDeﬁnitions
Kathleen M. Fox,1 John M. Brooks,2 ShravanthiR.Gandra,3 RichardMarkus,3
andChiun-FangChiou3
1Strategic Healthcare Solutions, LLC, P.O. Box 543, Monkton, MD 21111, USA
2College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA
3Amgen Inc., Thousand Oaks, CA 91320, USA
Correspondence should be addressed to Kathleen M. Fox, kathyfox@comcast.net
Received 12 February 2009; Accepted 2 May 2009
Recommended by David Ball
Objectives. Estimate and compare the proportion of cancer patients with cachexia using diﬀerent deﬁnitions from available clinical
data. Methods. Electronic medical records were examined to estimate the proportion of cancer patients with cachexia using 4
deﬁnitions: (1) ICD-9 diagnostic code of 799.4 (cachexia), (2) ICD-9 diagnosis of cachexia, anorexia, abnormal weight loss, or
feeding diﬃculties, (3) prescription for megestrol acetate, oxandrolone, somatropin, or dronabinol, and (4) ≥5% weight loss.
Patients with cancer of the stomach, pancreas, lung, colon/rectum, head/neck, esophagus, prostate, breast, or liver diagnosed
between 1999 and 2004 were followed for cachexia. Results. Of 8541 cancer patients (60% men and 55% Caucasian), cachexia
was observed in 2.4% of patients using the cachexia diagnostic code, 5.5% expanded diagnoses, 6.4% prescription medication
deﬁnition, and 14.7% with ≥5% weight loss. Conclusions. The proportion of patients with cachexia varied considerably depending
upon the deﬁnition employed, indicating that a standard operational deﬁnition is needed.
Copyright © 2009 Kathleen M. Fox et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Cachexia, often referred to as the wasting disease, is a
complex metabolic syndrome associated with underlying
illness and characterized by loss of muscle with or without
loss of fat mass [1, 2]. However, the prominent clinical
feature of cachexia is weight loss with anorexia, inﬂam-
mation, insulin resistance, and increased muscle protein
breakdown as additional frequent features [3, 4]. Patients
with gastric, pancreatic, colorectal, or lung cancer often
experience signiﬁcant weight loss, including loss of skeletal
muscle mass and develop cachexia with or without anorexia
[5–7]. It has been shown that at the time of diagnosis,
80% of patients with upper gastrointestinal cancer and 60%
of patients with lung cancer have already experienced a
signiﬁcant weight loss [8].
Cachexia is estimated to be the immediate cause of
death in 20% to 40% of cancer patients [1, 8]. Several
investigations have provided evidence that cancer patients
with signiﬁcant weight loss also report impaired quality of
life [9–11], decreased response to chemotherapy [7, 12], and
more frequent and severe toxicity [12]. The speciﬁc etiology
of cancer cachexia is not entirely understood since cachexia
can manifest in individuals with metastatic cancer as well as
in individuals with localized disease. Cachexia also does not
appear to be the result of tumor size, type, or extent [5].
However, due to its complex pathology and clinical
presentation, cachexia may be underdiagnosed. There is no
single, generally agreed-upon deﬁnition of cachexia [13, 14].
Since no standard deﬁnition of cachexia is available, cachexia
is infrequently identiﬁed, or diagnosed and rarely treated
[13,15].Therearenoapprovedmedicationstotreatcachexia
and its muscle wasting/loss apart from growth hormone and
some appetite stimulants [14]. Hence, physicians treat the
symptoms of anorexia, weight loss, and insulin resistance.
Additionally, physicians do not routinely assess or measure
muscle loss in their patients even though loss of muscle
mass is a hallmark sign of cachexia. Physicians may note2 Journal of Oncology
weight loss, weakness or fatigue in the patient’s medical
record and the patient may be given a diagnosis of anemia
or anorexia instead of cachexia. Thus, accurate estimates
of the prevalence of cachexia among cancer patients are
limited. It is essential to have a validated and universally
accepteddeﬁnitionofcachexiasoclinicianscanrecognizethe
problem and institute treatment [13, 14]. This retrospective
database study of electronic medical records was designed
to examine diﬀerent deﬁnitions of cachexia using available
clinical data sources and determine the variation in the
proportionofpatientswithcachexiausingfourdeﬁnitionsof
cachexia. The study objectives were to quantify the number
of patients identiﬁed with cachexia among cancer patients
and to characterize these patients with cachexia compared
with cancer patients without cachexia. The study was not
designed to identify the best deﬁnition or criteria but rather
to understand the potential variability in cachexia and
patient characteristics.
2. Methods
A retrospective database study of electronic medical records
was conducted to ascertain the variation in the proportion
of cancer patients with cachexia using four deﬁnitions of
cachexia: (1) ICD-9 code for cachexia (ICD-9-CM 799.4),
(2) ICD-9 code for cachexia, ICD-9-CM 783.0 for anorexia,
ICD-9-CM 783.2x for abnormal weight loss, or ICD-9-CM
783.3 for feeding diﬃculties, (3) at least one prescription for
megestrol acetate, oxandrolone, somatropin, or dronabinol,
and (4) ≥5% weight loss postcancer diagnosis. The ICD-9
diagnostic code of 799.4 states cachexia or wasting disease
with no deﬁnition of cachexia provided. The ﬁrst occurrence
of any one of the deﬁnition criteria was deﬁned as the
presence of cachexia. Since there is no consensus in the
ﬁeld on the deﬁnition of cachexia, 4 diﬀerent deﬁnitions
were used to understand the range in frequency of cachexia.
Thesedeﬁnitionswerechosensincethedatawouldbereadily
available in clinical practice and administrative databases.
All eligible cancer patients from the Henry Ford tumor
registry diagnosed between 1999 and 2004 were assessed
for the presence of cachexia, using each of the four study
deﬁnitions. Data from the Henry Ford Health System tumor
registry and electronic medical records was utilized to
identify cancer patients and assess the characteristics of
patients with cachexia. Henry Ford Health System (HFHS)
is one of the leading US vertically integrated health care
systems providing healthcare services to the Michigan and
Ohio region. The tumor registry includes information on
nearly 2500 newly diagnosed cancers annually, including
primary site, histological type, disease stage, and treatment
course. Electronic medical records were merged for eligible
cancer patients to obtain data on demographics, weight, and
comorbid conditions.
Eligible cancer patients included the following cancer
types: gastric, pancreatic, lung (nonsmall cell and small cell),
colorectal, head or neck, esophageal, prostate, breast, hepatic
or liver. These cancer types were included because estimates
from the US Cancer Statistics Working Group indicated that
85% of gastric cancer, 83% of pancreatic cancer, and 61% of
nonsmall cell lung cancer patients exhibit signiﬁcant weight
loss (≥5%), loss of muscle mass, and develop cachexia,
with or without the presence of anorexia [7]. Patients with
no tumor stage and those with a prior history of cancer
(as noted in patient’s admitting history and physical) were
excluded from the study. Patients were followed from date of
cancer diagnosis to death, date of drop-out or end of study
(December 2006) to determine the presence of cachexia.
For the ICD-9 diagnostic codes and prescription medication
deﬁnitions, a patient was identiﬁed as having cachexia if
the diagnosis or medication was present at the time of or
after the cancer diagnosis to ensure that all prevalent cases
of cachexia were identiﬁed. This could not be done for
the weight loss deﬁnition because weight prior to cancer
diagnosis was not available. Henry Ford Health System has
a stable population especially within oncology since they are
the largest healthcare insurer in the region and are a referral
center, thus the drop-out rate is minimal. The study was
approved by the Henry Ford Health System IRB.
Since physicians do not routinely assess loss of muscle
in usual clinical practice, diﬀerent deﬁnitions of cachexia
were developed to capture other possible features of cachexia
(weight loss) as well as diagnosis or treatment of conditions
associated with cachexia (e.g., anorexia, anabolic steroids,
and growth hormone) [13, 14]. The deﬁnitions were chosen
to provide a range for how cachexia may be identiﬁed
among cancer patients in clinical practice. Cachexia could
occur at time of the cancer diagnosis or after. Also, patient
identiﬁcation for cachexia was done independently for each
deﬁnition so some patients may be identiﬁed as having
cachexia in more than one deﬁnition. For example, a patient
may have a diagnosis of 799.4 and have ≥5% weight loss.
Body weight was abstracted from the electronic medical
records and percent change in weight was computed for
patients with serial weight measures postcancer diagnosis.
Due to the sporadic recording of weight, weight change
was computed from the time of the ﬁrst weight measure
after cancer diagnosis up to death or end of study. This
method provided a varying time period over which weight
loss was observed and the focus of the analysis was on the
presence of weight loss postdiagnosis rather than the severity
or rapidness of onset. A threshold of 5% body weight loss
was used since several studies have used this as a deﬁnition of
cachexia [13, 16, 17]. Major comorbid conditions including
stroke, coronary heart disease, peripheral vascular disease,
heart failure, hypertension, chronic pulmonary disease,
osteoarthritis, osteoporosis, and diabetes were abstracted
from the patient’s record to assess current health status.
These conditions were selected since they were known to
impact physical health, functioning, and activities of daily
living which may result in loss of muscle mass or weight
unrelated to their cancer.
2.1. Statistical Analyses. Analyses were conducted for all
cancer types combined. The proportion of patients for
categorical variables and mean and standard deviation
for continuous variables were computed for patients with
cachexia compared with patients without cachexia (no ICD-
9 diagnostic code, no prescription medications, and noJournal of Oncology 3
weight loss ≥5%). Number of patients with cachexia (from
2000 to 2006) was estimated for each of the 4 deﬁnitions.
The number of patients with cachexia was the numerator
and the number of patients with the selected cancers was
the denominator in computing proportions with cachexia.
The length of follow up after cancer diagnosis in which
to identify cachexia may diﬀer between patients diagnosed
in 1999 and those diagnosed in 2000 or later. Thus, the
identiﬁcation of cachexia did not start until 2000 to adjust
for duration of cancer and follow-up time before cachexia
was noted. Patients identiﬁed as having cachexia for each
deﬁnition were compared with patients who did not meet
any of the 4-deﬁnition criteria (no cachexia). Comparisons
were made using t-tests for means and chi-square tests
for proportions. No statistical adjustment was made for
multiple comparisons. Percent agreement (proportion of
concordant results among all tested) between diﬀerent
cachexia deﬁnitions was computed to assess the concordance
between any 2 deﬁnitions. Since a gold standard deﬁnition
was not available, percent agreement (instead of sensitivity,
speciﬁcity, or predictive value) was used.
3. Results
There were 8541 cancer patients who were diagnosed with
cancer between January 1999 and December 2004 and
included in the study. Of the total sample, 39% of patients
had prostate cancer, 25% breast, 15% lung, 11% colorectal,
3%head/neck,3%pancreatic,2%liver,2%gastric,and1.4%
esophageal cancer. The rank order of cancer type within the
Henry Ford tumor registry is the same as the SEER registry
for 2000–2004 [16]. Mean age for eligible cancer patients was
63.6 (11.8) years, 60% were men, 55% were Caucasian, and
36% were African-American. Less than one-third of patients
(29%) died during the study period.
3.1. Cachexia Based on ICD-9 Diagnostic Codes. There were
205outof8541(2.4%)cancerpatientswithanICD-9codeof
799.4 for cachexia during the follow-up period from cancer
diagnosistoendofthestudy.Theaverageageofpatientswith
the diagnostic code for cachexia was 66 years and 34% were
men(Table 1).Patientswiththecachexiadiagnosticcodehad
signiﬁcantly more comorbidity, especially coronary heart
disease, heart failure, hypertension, and COPD than patients
without cachexia (without any of the cachexia deﬁnition
criteria) (P<. 01) (Table 1). The largest proportion of
patients with a cachexia diagnostic code had lung cancer
(40.5%)andsigniﬁcantlymorepatientshadlung,esophagus,
gastric, or head/neck cancer compared with patients without
cachexia. Cachexia was diagnosed in more patients with
regional (49%) or distant (31%) metastatic cancer than in
situ or local stages. Approximately 13% of patients with
esophageal cancer had a diagnostic code for cachexia; less
than 10% of the other cancer types had the diagnostic code.
The expanded ICD-9 diagnostic code deﬁnition includ-
ing codes for cachexia, anorexia, abnormal weight loss
and feeding diﬃculties identiﬁed 467 patients out of 8541
(5.5%) patients. Similar to the cachexia diagnostic code
only, patients with the expanded code deﬁnition were mostly
women (63%), mean age of 67 years, with substantial
cardiovascular comorbidity (Table 1). A signiﬁcantly greater
proportion of cachexia patients had each of the comorbid
conditions compared with patients without cachexia, P<
.01 (Table 1). Signiﬁcantly more patients with cachexia had
esophageal, gastric, head/neck or lung cancer compared
with patients without cachexia, P<. 01. Signiﬁcantly
more patients with cachexia had regional (41%) or distant
(21%) tumor stages than patients without cachexia (24%
regional and 12% distant), P<. 01. Approximately 21%
of patients with esophageal cancer, 17% of patients with
head/neck cancer, and 16% of patients with gastric cancer
had cachexia based upon the expanded diagnostic codes
deﬁnition. Less than 10% of patients with breast, colorectal,
liver, lung, pancreatic, or prostate cancer had cachexia using
this deﬁnition.
3.2. Cachexia Based upon Prescription Medication Use. Using
the deﬁnition of prescription for megestrol acetate, oxan-
drolone,somatropinordronabinol,546(6.4%)patientswere
identiﬁed as having cachexia. Signiﬁcantly more patients
taking a medication for possible treatment of cachexia
were men and had cardiovascular disease, COPD, and
diabetes compared with patients without cachexia, P<. 01
(Table 1). For patients taking cachexia-related medications,
34% had lung, 21% had breast, and 16% had prostate cancer.
A signiﬁcantly greater proportion of the patients taking
cachexia-related medications had regional or distant stage
tumors compared with patients without cachexia, P<. 01.
3.3.CachexiaBasedupon ≥5%WeightLoss. Amongthe8541
cancer patients, 65% of patients had body weight recorded
in the electronic medical record and 3343 (39% of total)
patientshad2ormoreweightsforthecomputationofweight
loss after cancer diagnosis. Among the patients with 2 or
more weight measurements, 1257 had ≥5% weight loss,
which represents 14.7% of the total sample of 8541 and
37.6% of patients with ≥2 weight measurements. The mean
time over which weight loss was observed was 655 (538)
days, with a median of 487 days and interquartile range
of 236–942. There were signiﬁcantly more patients in the
≥5% weight loss/cachexia group with cardiovascular disease
and diabetes compared with patients without cachexia by
any deﬁnition, P<. 01 (Table 1). The largest proportion
of patients with ≥5% weight loss (n = 1257) had breast
cancer (31%) or prostate cancer (29%). Patients with ≥5%
weight loss were more likely to have regional (P< . 01) but
not distant stage tumors compared with patients without
cachexia. Approximately 20% of patients with gastric (n =
171) or head/neck cancers (n = 256) had ≥5% weight loss,
and 19% of the 2135 patients with breast cancer and 16-17%
of patients with colorectal (n = 939), esophageal (n = 120),
or liver (n = 171) cancer had ≥5% weight loss after their
cancer was diagnosed and before the study ended.
The proportion of cancer patients with cachexia varied
across cancer type and by cachexia deﬁnition (Table 2). As
low as 0.8% of breast cancer patients were identiﬁed as
having a diagnosis of cachexia (ICD-9 code of 799.4) but as
many as 19% of breast cancer patients had signiﬁcant weight4 Journal of Oncology
Table 1:Characteristicsofcancer patientsidentiﬁedashavingcachexia basedonthediﬀerentdeﬁnitionsandcomparedwithcancer patients
without cachexia.
Characteristics
Cancer patients
with cachexia
ICD-9 code
(799.4) n = 205
Cancer patients
with cachexia
ICD-9 codes
(cachexia,
anorexia,
abnormal weight
loss, or feeding
diﬃculties)
n = 467
Cancer patients
with prescription
for megestrol
acetate,
oxandrolone,
somatropin or
dronabinol
n = 546
Cancer patients
with weight loss
≥5% n = 1257
Cancer patients
with cachexia by
any deﬁnition
n = 1975
Cancer patients
without
cachexia† n =
6,566
Age, years, mean 65.6∗ 66.9∗∗ 64.4∗ 66.3∗∗ 65.8∗∗ 63.0
Gender, men, % 34.1 37.0 46.7∗∗ 49.7∗∗ 46.9∗∗ 38.4
Comorbidities, %
Stroke 3.9 11.9∗∗ 7.9∗∗ 4.9 6.5∗∗ 3.8
CHD 27.3∗∗ 35.1∗∗ 33.7∗∗ 26.8∗∗ 29.5∗∗ 16.7
Peripheral vascular
disease 4.4 7.9∗∗ 4.8∗∗ 5.1∗∗ 5.3∗∗ 2.5
CHF 24.9∗∗ 28.5∗∗ 21.6∗∗ 17.6∗∗ 20.5∗∗ 10.0
Hypertension 54.2∗∗ 67.0∗∗ 60.8∗∗ 56.1∗∗ 58.7∗∗ 43.6
COPD 38.1∗∗ 32.6∗∗ 26.2∗∗ 18.1∗∗ 21.6∗∗ 11.4
Osteoarthritis 11.7 25.1∗∗ 15.9∗∗ 19.1∗∗ 18.9∗∗ 11.7
Osteoporosis 3.9 5.8∗∗ 5.1∗∗ 5.0∗∗ 4.8∗∗ 3.0
Diabetes 16.6 24.4∗∗ 24.0∗∗ 26.3∗∗ 25.9∗∗ 17.2
Cancer type, %
Breast 8.8 ∗∗ 13.9∗∗ 20.5 31.3∗∗ 26.5∗ 24.2
Colorectal 11.2 11.8 10.3 11.8 11.7 10.3
Esophagus 7.3∗∗ 5.1∗∗ 2.9∗∗ 1.5 2.5∗∗ 1.0
Gastric 5.9∗∗ 4.7∗∗ 5.0∗∗ 2.2∗ 3.0∗∗ 1.3
Head/neck 7.3∗∗ 9.0∗∗ 2.8 3.9∗∗ 4.6∗∗ 2.4
Liver 2.4 2.1 1.1 2.1 1.9 1.8
Lung 40.5∗∗ 26.8∗∗ 33.5∗∗ 15.6 20.3∗∗ 13.6
Pancreas 3.9 3.4 7.9∗∗ 2.2 3.9∗∗ 2.2
Prostate 12.7∗∗ 23.1∗∗ 16.1∗∗ 29.4∗∗ 25.7∗∗ 43.3
Tumor stage, %
In situ 0.5∗∗ 2.4∗∗ 3.5∗∗ 8.4 6.6 6.9
Local 16.6∗∗ 33.0∗∗ 25.5∗∗ 50.4∗ 42.3∗∗ 54.3
Regional 48.8∗∗ 41.1∗∗ 39.2∗∗ 28.2∗∗ 31.9∗∗ 24.3
Distant 31.2∗∗ 21.1∗∗ 28.9∗∗ 10.7 16.9∗∗ 12.1
Unknown 2.9 2.4 2.9 2.3 2.4 2.4
†No cachexia based on any of the 4 deﬁnitions (no ICD-9 diagnostic codes, prescription medications or ≥5% weight loss).
∗P<. 05, ∗∗P<. 01 chi-square test or t-test comparing each cachexia deﬁnition to cancer patients without cachexia.
Stroke/TIA ICD-9 code = 435.xx, 436.xx, CHD = 410.xx, 411.xx, 412.xx, 414.xx, 429.2, 440.xx or procedures = 36.0x, 36.1x, 38.12–38.14, 38.16, 38.18,
38.34, 38.44, 39.22–39.26, 39.50 or CPT codes = 33510–33516, 33517–33545, 33572, 33877, 34800–34832, 35061–35103, 35301, 35311–35381, 35390, 35450–
35481, 35482–35495, 35500–35683, 92980–92981, 92982–92984, 92995–92966, PVD = 443.xx, 39.29, CHF = 428.xx, hypertension = 401.xx, 402.xx, 404.xx,
osteoarthritis = 715.xx, osteoporosis = 733.00–733.09, 737.40, 737.41, COPD = 493.20–493.22, 496, 491.00–491.21, 491.8, 491.9, diabetes = 250.xx, 362.0x,
366.41.
loss (≥5%). Approximately 19-20% of patients with gastric
cancer had cachexia based on the prescription medication
and weight loss deﬁnitions but only 8% had received a
diagnostic code for cachexia.
3.4. Cachexia by Any Deﬁnition. Cancer patients who met
the criteria for any of the four cachexia deﬁnitions were
identiﬁed and 1975 (23%) patients met at least one of the
deﬁnitions for cachexia. Comparing patients with cachexia
using any one of the deﬁnitions with cancer patients without
cachexia, cachexia patients were older and greater percent-
ages were men and had comorbid conditions compared
with the patients without cachexia (Table 1). The largest
proportion of cachexia patients had breast (27%), prostateJournal of Oncology 5
Table 2: Proportion of cancer patients with cachexia by cancer type.
Cancer type
Cancer patients
with cachexia
ICD-9 code only
Cancer patients
with any cachexia
ICD-9 code
Cancer patients
taking prescription
medication
indicative of
cachexia
Cancer patients
with ≥5% weight
loss
Cancer patients
with any one of the
cachexia
deﬁnitions
Breast, n = 2112 0.8% 3.1% 5.3% 18.6% 24.8%
Colorectal, n = 905 2.5% 6.1% 6.2% 16.4% 25.5%
Esophagus, n = 117 12.8% 20.5% 13.7% 16.2% 41.9%
Gastric, n = 142 8.4% 15.5% 19.0% 19.7% 41.5%
Head/neck, n = 246 6.1% 17.1% 6.1% 19.9% 37.0%
Liver, n = 153 3.3% 6.5% 3.9% 17.0% 24.2%
Lung, n = 1291 6.4% 9.7% 14.2% 15.2% 31.1%
Pancreas, n = 221 3.6% 7.2% 19.5% 12.7% 34.8%
Prostate, n = 3354 0.8% 3.2% 2.6% 11.0% 15.1%
(26%), or lung (20%) cancer. Over 41% of patients with
esophageal or gastric cancer, 37% of patients with head/neck
cancer, 35% of patients with pancreatic cancer and 31% of
patients with lung cancer met at least one of the cachexia
deﬁnitions.
The amount of overlap between cachexia deﬁnitions was
limited. Less than 22% of patients were classiﬁed as having
cachexia based on prescription medications and either an
ICD-9 diagnostic code or ≥5% weight loss (Figure 1). The
overall percent agreement between the medication-deﬁned
cachexia and ICD-9 cachexia diagnostic code only deﬁnition
was 93%, 91% for the extended diagnostic codes, and 81%
for the weight loss deﬁnition. Less than 7% of patients were
classiﬁed as having cachexia based on weight loss and either
an ICD-9 code or prescription medication (Figure 2). The
overall percent agreement between the weight loss deﬁnition
and ICD-9 code for cachexia only was 84%, 81% for the
extended diagnostic codes, and 81% for the medications
deﬁnition. By deﬁnition, all patients with an ICD-9 code of
799.4 were included in the ﬁrst two deﬁnitions (ICD-9 code
of 799.4 and the expanded codes of cachexia, anorexia, or
feeding diﬃculties).
4. Discussion
This study determined that the proportion of patients with
cachexia varied considerably depending upon the deﬁnition
employed, from 2.4% with the cachexia only diagnostic code
to 15% with the weight loss deﬁnition. Additionally, up to
23% of cancer patients may have cachexia at some point
after their cancer diagnosis as determined by any of the
four deﬁnitions. The ≥5% weight loss deﬁnition identiﬁed
the most patients with cachexia (15%) and weight loss is
considered a hallmark symptom of cachexia [13]b u tn o t
the only symptom. These ﬁndings highlight the need for
a uniﬁed deﬁnition of cachexia since the proportion of
patients identiﬁed varied widely and this variation would
make it diﬃcult to estimate the need for resources to
identify and treat patients with cachexia. Work is underway
to develop a uniﬁed deﬁnition of cachexia [13]. Also, the
ICD-9 code
779.4
Expanded
ICD-9 codes
  
weight
loss
Rx
medications
11.2% 14.3%
20.5%
≥5%
Figure 1: Pair-wise overlap between cachexia deﬁnitions and
prescription medication deﬁnition.
ICD-9 code
779.4
Expanded
ICD-9 codes
        weight loss
Rx
medications
2.2% 6.1%
5%
≥5%
Figure 2: Pair-wise overlap between cachexia deﬁnitions and
weight loss deﬁnition.
proportions identiﬁed with cachexia from each deﬁnition
and the combined deﬁnition may underrepresent the true
frequency of cachexia among cancer patients. The possible
underestimation of cachexia may be due to several factors6 Journal of Oncology
including limited therapeutic interventions for cachexia
which may lead to it not being coded and the lack of weight
loss data prior to the cancer diagnosis. In a study of 119
patients with advanced gastrointestinal cancer, investigators
found that 81% had weight loss of >5% over 3 months
[9]. Similarly, in 3000 cancer patients from the Eastern
Cooperative Oncology Group clinical trials, weight loss of
>5% was observed in 85% of gastric, 83% in pancreatic,
61% of nonsmall cell lung, 57% of small cell lung, and
54% of colon cancer patients [7]. The proportion of patients
with cachexia in the present study was lower than those
found in the Eastern Cooperative Oncology Group [7].
However, the Oncology Group estimated incidence rates of
weight loss shortly after diagnosis and over 2 to 6 months
before receiving treatment and the present study estimated
proportion of patients with cachexia of all tumor stages and
treatments. Also, the present study was among US patients
versus United Kingdom patients and data capture of weight
and weight loss may not be as consistent in the US as it is in
a national healthcare system.
In comparing the proportions of patients with cachexia
observed in the present study across the diﬀerent deﬁnitions,
it is apparent that a diagnosis of cachexia is given to a
minority of patients (2.4%). Expanding the diagnostic codes
to other conditions that may be surrogates for cachexia
(i.e.,anorexia,abnormalweightloss,andfeedingdiﬃculties)
doubled the estimate for cachexia but did not approach the
proportion based on ≥5% weight loss. This discrepancy may
conﬁrm anecdotal information that suggests that physicians
may diagnose but not code for billing purposes abnormal
weight loss among their cancer patients. Physicians do
not receive any additional reimbursement for patients with
abnormal weight loss so they may not include the weight
loss in the diagnostic codes for billing and therefore it does
not appear in the claims databases. Additionally, diagnostic
codes may be used only in extreme cases (those appearing to
be visually wasting) towards end of life as opposed to earlier
diagnosis at a time when the course of the disease can be
changed through interventions.
Cachexia also may not be widely treated since only 6.4%
of patients were taking prescription hormones, anabolic
steroids,orappetitestimulantsandthereisnoFDAapproved
treatment for cachexia [13, 14]. Physicians may believe that
available treatments are not eﬀective or appropriate for long-
term use and hence not used; therefore, this deﬁnition
may not be a good surrogate for identifying cachexia. Data
demonstrating the eﬀectiveness of pharmacologic agents
like androgens and growth hormone in treating cachexia is
lacking [13].
Given the large variation in estimates across cachexia
deﬁnitions, a standard, operational deﬁnition of cachexia
is needed [13, 14]. Depending upon the deﬁnition of
cachexia, the burden of cachexia in terms of mortality,
health-related quality of life, healthcare resource utilization,
and economics to health plans and society will vary widely
making it diﬃcult to identify and manage patients with
cachexia. Without a standard deﬁnition, physicians are
unlikely to identify, diagnose, and treat all cases of cachexia,
which leaves patients vulnerable to higher mortality, and
decreased quality of life [13, 14]. The lack of a standard
deﬁnition also hinders healthcare decision makers’ ability
to plan appropriate resources and treatment for cachexia
patients. For cancer patients, the diagnosis and treatment of
cachexia will become important goals to improve morbidity,
mortality and quality of life [13]. Once a uniﬁed deﬁnition
of cachexia is developed, further research will be needed
to determine the prevalence of cachexia among cancer
patients.
When cachexia patients were compared with patients
without cachexia, cachexia patients had more comorbid
conditions, especially CHD, heart failure, hypertension,
and COPD. This may indicate that cachexia patients have
multiple health conditions including their cancer that may
lead to a weakened state which may cause the cachexia to
be diagnosed or exacerbate it. Also, patients with cachexia
had more distant metastatic tumors compared with patients
without cachexia.
The present study has limitations that should be consid-
ered.Thestudypopulationincludedonlyindividualsseeking
care at the Henry Ford Health System and cancer patients
seeking care at Henry Ford may not be representative of all
cancer patients. Thus, caution in generalizing the ﬁndings
beyond the Henry Ford Health System is needed. However,
this is the largest study and the ﬁrst US study of cachexia
using available clinical data. Patients who had a shorter
follow-up time for estimating cachexia (i.e., dropped out of
Henry Ford Health System) may be diﬀerent from those with
complete follow-up time, but Henry Ford Health System has
a stable patient population and is one of the largest referral
centers in the region. Data prior to the cancer diagnosis
was not available so some prevalent cases of cachexia that
developed prior to the cancer diagnosis may not have been
included. This may have aﬀected the weight loss deﬁnition
of cachexia more than the other deﬁnitions because weight
loss prior to the cancer diagnosis could not be assessed. For
patients with more than one weight measurement, weight
loss was computed from the ﬁrst weight measure after cancer
diagnosis to the second weight measure. Thus, the time
period for assessing weight loss varied over time for patients
with weight loss ≥5%. The clinical course of a patient losing
≥5% of weight over 1–2 months is very diﬀerent than a
patient losing the weight over 12 or more months; however,
this study focused on the presence of weight loss and not
the time course or severity of the weight loss. Also, weight
loss due to reversible causes like treatment side eﬀects or
mechanical GI obstruction could not be ruled out and was
classiﬁed as cachexia in this study if it was ≥5%. Since
there is no widely used clinical deﬁnition of cachexia and
physicians do not typically measure muscle loss in cancer
patients, cachexia is likely to be an underutilized diagnosis
and under-coded ICD-9 code. Thus, the study deﬁnitions
of cachexia by ICD-9 codes and prescription medications
included anorexia, which may not be true clinical cases of
c a c h e x i a ;t h u so u re s t i m a t e so fc a c h e x i am a yb ea no v e r -
estimation. Also, there may be a survival bias across the
deﬁnitions of cachexia so the identiﬁcation of cachexia may
be confounded by the length of follow up. For example,
patients in the weight loss deﬁnition were followed atJournal of Oncology 7
least until 2-weight measures were recorded compared with
patients with a diagnostic code for cachexia.
In conclusion, each cachexia deﬁnition provided a diﬀer-
ent estimate of the proportion of patients with cachexia. If
all four deﬁnitions are utilized to identify cachexia patients,
approximately 23% of cancer patients will have cachexia
at some time after their cancer diagnosis. This does not
include the proportion of patients that had unintentional
weight loss leading up to the cancer diagnosis. A standard,
well-accepted deﬁnition of cachexia is needed to improve
clinical research and diagnosis and treatment of cachexia,
and work is underway [13]. Unintentional weight loss of
≥5% may be the best criteria currently to alert clinicians that
detailed follow up for cachexia may be needed after ruling
out reversible causes of weight loss.
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